Results 261 to 270 of about 27,891 (313)

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA Intern Med
Pop-Busui R, Rasmussen S, Deanfield JE, Buse JB, Marx N, Mulvagh SL, Inzucchi SE, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Hovingh GK, Bayer Tanggaard K, Birkenfeld AL, Connelly KA, Haluzik M, Cavender MA, Kellerer M, Jhund PS, Gregersen S, Nielsen OW, Lam CSP, McGuire DK, SOUL Study Group.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Semaglutide

Reactions Weekly
  +34 more sources

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

New England Journal of Medicine
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Arun J. Sanyal, Philip N. Newsome, Iris Kliers, L. Østergaard, Michelle T. Long, M. Kjær, Anna M G Cali, Elisabetta Bugianesi, M. Rinella, Michael Roden, Vlad Ratziu   +10 more
semanticscholar   +1 more source

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

New England Journal of Medicine
BACKGROUND Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate these risks is unknown.
V. Perkovic, Katherine R. Tuttle, P. Rossing, Kenneth W Mahaffey, J. Mann, G. Bakris, F. Baeres, T. Idorn, H. Bosch‐Traberg, N. Lausvig, R. Pratley   +10 more
semanticscholar   +1 more source

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

New England Journal of Medicine
BACKGROUND Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS In this phase 3b,
Louis J. Aronne, D. B. Horn, C. L. le Roux, Wayne Ho, B. Falcon, Elisa Gomez Valderas, Sagar Das, Clare J. Lee, Leonard C Glass, Cagri Senyucel, J. Dunn   +10 more
semanticscholar   +1 more source

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

New England Journal of Medicine
BACKGROUND The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk.
Darren K. McGuire, N. Marx, S. Mulvagh, J. Deanfield, S. Inzucchi, R. Pop-Busui, J. Mann, S. Emerson, Neil R. Poulter, M. D. Engelmann, M. Ripa, G. Hovingh, K. Brown-Frandsen, Stephen C. Bain, M. Cavender, Mette Gislum, J. David, J. Buse   +17 more
semanticscholar   +1 more source

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

JAMA psychiatry
Key Points Question Does the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol consumption and craving in adults with alcohol use disorder (AUD)?
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, Georgios Kostantinis, Thomas Gilmore, Neil R Sullivan, A. Tow, Sarah S. Dermody, Mark A. Prince, Robyn A. Jordan, Sherry A. McKee, Paul J. Fletcher, E. Claus, Klara R. Klein   +13 more
semanticscholar   +1 more source

Semaglutide

Reactions Weekly, 2023
  +7 more sources